Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921468 | 0.97 | CASP2 (0.45) | CASP2DNM1FAAHCYP2C9CYP2C19 | |
| SCHEMBL13033278 | 0.90 | CASP2 (0.57) | CASP2FAAHSLC6A5GRIA1NAAA | |
| SCHEMBL13033274 | 0.90 | CASP2 (0.57) | CASP2FAAHSLC6A5GRIA1NAAA | |
| SCHEMBL13033271 | 0.90 | CASP2 (0.57) | CASP2FAAHSLC6A5GRIA1NAAA | |
| SCHEMBL13033273 | 0.90 | CASP2 (0.57) | CASP2FAAHSLC6A5GRIA1NAAA | |
| SCHEMBL13033276 | 0.90 | CASP2 (0.57) | CASP2FAAHSLC6A5GRIA1NAAA | |
| SCHEMBL13033266 | 0.87 | MEN1 (0.48) | DNM1CYP2C9CYP2C19KDM4AHIF1A | |
| SCHEMBL20975887 | 0.86 | CASP2 (0.53) | CASP2SLC6A5GRIA1CTSD | |
| SCHEMBL9921436 | 0.86 | KMT2A (0.44) | CASP2DNM1FAAHCYP2C9CYP2C19 | |
| SCHEMBL14269661 | 0.86 | DNM1 (0.39) | CASP2DNM1FAAHCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100292432-A1 | POLYMERS FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010127154-A1 | POLYMERS FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127159-A2 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | CASP2 4375/4885DNM1 1864/4885FAAH 4073/4885 |
| US-20130266617-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | CASP2 4375/4885DNM1 1864/4885FAAH 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.